Celldex Therapeutics (CLDX) vs ImmuCell (ICCC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmuCell (ICCC) has outperformed Celldex Therapeutics (CLDX) over the past year, gaining 50.2% versus a gain of 16.1%. Over five years, ICCC leads with a +4.4% price change compared with -34.1% for CLDX. Celldex Therapeutics is the larger company by market cap ($2.28 billion vs $88.5 million), about 25.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDX | ICCC |
|---|---|---|
| Share price | $29.05 | $9.74 |
| Market cap | $2.28B | $88.46M |
| 1-day change | -4.54% | +0.52% |
| YTD return | +12.04% | +57.56% |
| 1-year return | +16.06% | +50.23% |
| 5-year return | -34.11% | +4.42% |
| P/E ratio (TTM) | — | 139.14 |
| EPS (TTM) | $-4.35 | $0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54M | — |
| Revenue growth (YoY) | -77.99% | — |
| Net income (latest FY) | $-258.76M | — |
| Gross margin | 87.06% | — |
| Operating margin | -18599.81% | — |
| Net margin | -16748.03% | — |
| 52-week high | $45.14 | $12.10 |
| 52-week low | $22.10 | $4.52 |
| Distance from 52-week high | -35.64% | -19.50% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +117.11% | — |
| Average volume | 1.27M | 22.88K |
| Shares outstanding | 78.53M | 9.08M |
| Employees | 198 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Celldex Therapeutics is about 25.8 times larger than ImmuCell by market value ($2.28B vs $88.46M).
- ICCC has outperformed CLDX by 34.2 percentage points over the past year.
About Celldex Therapeutics
CLDX stock →Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees
CLDX vs ICCC FAQ
Which is bigger, Celldex Therapeutics or ImmuCell?
Celldex Therapeutics (CLDX) is larger, with a market capitalization of $2.28B compared with $88.46M for ImmuCell (ICCC).
Which stock has performed better over the past year, CLDX or ICCC?
ICCC returned +50.23% over the past 12 months, compared with +16.06% for CLDX (price return, excluding dividends). Past performance does not predict future results.
Are Celldex Therapeutics and ImmuCell in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.